Antibody Production Market by Antibody Type, Process, End-User - Global Forecast 2025-2030- Product Image

Sale

Antibody Production Market by Antibody Type, Process, End-User - Global Forecast 2025-2030

Report
197 Pages
October 2024
Region: Global
360iResearch™
ID: 5888112

UP TO €681EUR$697USD£568GBP OFF until Dec 31^st 2024

The Antibody Production Market grew from USD 17.97 billion in 2023 to USD 20.16 billion in 2024. It is expected to continue growing at a CAGR of 12.40%, reaching USD 40.77 billion by 2030.

Antibody production refers to the biological process of generating antibodies, which are proteins used by the immune system to neutralize pathogens such as bacteria and viruses. The market for antibody production is driven by the increasing prevalence of infectious diseases, cancer, and autoimmune disorders requiring novel therapeutic strategies. Antibodies are essential in research and diagnostics, therapeutics, and biotechnology industries, with applications ranging from monoclonal antibodies in targeted cancer therapies to diagnostic tools in clinical labs. The necessity of this market stems from the growing demand for personalized medicine and advanced drug development, which requires highly specific and efficient antibody products.

Key growth factors include advancements in biotechnology, such as genetic engineering and hybridoma technology, enabling the development of novel antibody formats. The rise of biopharmaceuticals, with antibodies forming a substantial part of new drug pipelines, further bolsters market growth. Potential opportunities lie in developing cost-effective production methods and enhancing antibody specificity and affinity through techniques like phage display or CRISPR-based modifications. A strategic focus on facilitating integration with emerging fields like synthetic biology and precision medicine could yield competitive advantages.

However, market growth is constrained by high production costs, regulatory complexities, and the technical challenges associated with antibody engineering. These factors necessitate substantial investments in research and infrastructure, which can be a barrier for new entrants. Furthermore, the lengthy approval processes for antibody-based therapeutics can delay market entry.

Innovation opportunities are vast, focusing on improving production efficiency through bioprocessing innovations and exploring bispecific antibodies for multifaceted therapeutic approaches. Pursuing collaborations with academic institutions and technology firms for R&D can accelerate advancements. The market is dynamic, characterized by intense competition and rapid technological evolution, necessitating continual innovation and adaptation to emerging trends and regulatory landscapes to maintain a competitive edge.

Understanding Market Dynamics in the Antibody Production Market

The Antibody Production Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Rising prevalence of chronic diseases among population
- Growing demand for targeted therapies and personalized medicines
- Modernization of healthcare infrastructure and increase in healthcare expenditure
Market Restraints
- High costs associated with antibody production
Market Opportunities
- Robust research activities to introduce novel plant‐made monoclonal antibody
- Emerging applications of bispecific antibodies in cancer immunotherapy
Market Challenges
- Stringent regulatory frameworks for antibody production

Exploring Porter’s Five Forces for the Antibody Production Market

Porter’s Five Forces framework further strengthens the insights of the Antibody Production Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Antibody Production Market

External macro-environmental factors deeply influence the performance of the Antibody Production Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Antibody Production Market

The Antibody Production Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Antibody Production Market

The Antibody Production Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Antibody Production Market

The Antibody Production Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibody Production Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Cell Signaling Technology, Inc., Eppendorf AG, F. Hoffmann-La Roche Ltd., Fibercell Systems Inc, GE HealthCare Technologies Inc., Genmab A/S, GenScript Biotech Corporation, Gilead Sciences, Inc., INTEGRA Biosciences AG, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pall Corporation, Pfizer Inc., ProteoGenix, Sanofi S.A., Sartorius AG, Teva Pharmaceutical Industries Ltd., The Antibody Company, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Production Market to forecast the revenues and analyze trends in each of the following sub-markets:

Antibody Type
- Monoclonal Antibodies
- Polyclonal Antibodies
Process
- Downstream Processing
  - Chromatography Resins
  - Chromatography Systems
- Filtration
  - Consumables & Accessories
  - Filtration Systms
- Upstream Processing
  - Bioreactors
  - Consumables
End-User
- Contract Research Organizations (CROs)
- Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Research Institutes & Academic Centers

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of chronic diseases among population
5.1.1.2. Growing demand for targeted therapies and personalized medicines
5.1.1.3. Modernization of healthcare infrastructure and increase in healthcare expenditure
5.1.2. Restraints
5.1.2.1. High costs associated with antibody production
5.1.3. Opportunities
5.1.3.1. Robust research activities to introduce novel plant-made monoclonal antibody
5.1.3.2. Emerging applications of bispecific antibodies in cancer immunotherapy
5.1.4. Challenges
5.1.4.1. Stringent regulatory frameworks for antibody production
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Antibody Production Market, by Antibody Type

6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Polyclonal Antibodies

7. Antibody Production Market, by Process

7.1. Introduction
7.2. Downstream Processing
7.2.1. Chromatography Resins
7.2.2. Chromatography Systems
7.3. Filtration
7.3.1. Consumables & Accessories
7.3.2. Filtration Systms
7.4. Upstream Processing
7.4.1. Bioreactors
7.4.2. Consumables

8. Antibody Production Market, by End-User

8.1. Introduction
8.2. Contract Research Organizations (CROs)
8.3. Diagnostic Laboratories
8.4. Pharmaceutical & Biotechnology Companies
8.5. Research Institutes & Academic Centers

9. Americas Antibody Production Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Antibody Production Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Antibody Production Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. ANTIBODY PRODUCTION MARKET RESEARCH PROCESS
FIGURE 2. ANTIBODY PRODUCTION MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ANTIBODY PRODUCTION MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. ANTIBODY PRODUCTION MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. ANTIBODY PRODUCTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTIBODY PRODUCTION MARKET DYNAMICS
TABLE 7. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY RESINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION SYSTMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 50. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 51. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 52. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 56. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 57. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 58. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 80. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 81. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 82. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 83. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 84. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 86. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 87. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 88. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 89. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 90. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 95. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 98. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 99. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 100. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 101. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 102. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 104. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 105. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 106. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 107. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 110. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 111. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 112. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 113. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 116. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 117. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 118. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 122. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 123. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 124. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 128. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 129. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 130. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 134. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 135. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 136. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 137. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 138. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 140. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 141. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 152. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 153. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 154. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 155. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 156. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 157. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 159. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 160. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 161. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 162. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 163. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 165. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 166. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 167. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 168. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 169. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 171. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 172. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 173. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 174. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 175. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 177. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 178. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 179. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 180. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 181. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 189. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 190. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 191. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 192. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 193. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 200. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 201. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 207. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 208. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 209. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 210. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 211. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 212. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 213. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 214. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 215. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 216. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 217. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 219. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 220. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 221. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 222. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 223. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 242. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 243. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 244. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 245. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 246. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 247. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 260. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 261. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 262. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 263. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 264. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 265. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 278. ANTIBODY PRODUCTION MARKET SHARE, BY KEY PLAYER, 2023
TABLE 279. ANTIBODY PRODUCTION MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Antibody Production Market, which are profiled in this report, include:

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Biogen Inc.
Bristol-Myers Squibb Company
Cell Signaling Technology, Inc.
Eppendorf AG
F. Hoffmann-La Roche Ltd.
Fibercell Systems Inc
GE HealthCare Technologies Inc.
Genmab A/S
GenScript Biotech Corporation
Gilead Sciences, Inc.
INTEGRA Biosciences AG
Merck KGaA
Novartis AG
Novo Nordisk A/S
Pall Corporation
Pfizer Inc.
ProteoGenix
Sanofi S.A.
Sartorius AG
Teva Pharmaceutical Industries Ltd.
The Antibody Company
Thermo Fisher Scientific Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	197
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 20.16 Billion
Forecasted Market Value ( USD ) by 2030	$ 40.77 Billion
Compound Annual Growth Rate	12.4%
Regions Covered	Global
No. of Companies Mentioned	26

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3464EUR$3,545USD£2,892GBP €3849EUR$3,939USD£3,213GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6128EUR$6,272USD£5,116GBP €6809EUR$6,969USD£5,684GBP

Understanding Market Dynamics in the Antibody Production Market

Exploring Porter’s Five Forces for the Antibody Production Market

Applying PESTLE Analysis to the Antibody Production Market

Analyzing Market Share in the Antibody Production Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Antibody Production Market

Strategic Recommendations for Success in the Antibody Production Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Monoclonal Antibodies Market by Source Type, Production Type, Indication, End-User - Global Forecast 2025-2030

Mammalian Polyclonal IgG Antibody Market by Source, Product, Application, End-User - Global Forecast 2025-2030

Antibody Production - Global Strategic Business Report

Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030

Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Forecast to 2029

About the Antibody Production Market